(NASDAQ: GNLX) Genelux's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.42%.
Genelux's earnings in 2026 is -$33,581,000.On average, 8 Wall Street analysts forecast GNLX's earnings for 2026 to be -$37,275,838, with the lowest GNLX earnings forecast at -$39,988,683, and the highest GNLX earnings forecast at -$34,841,003. On average, 7 Wall Street analysts forecast GNLX's earnings for 2027 to be -$34,849,971, with the lowest GNLX earnings forecast at -$40,867,555, and the highest GNLX earnings forecast at -$26,366,165.
In 2028, GNLX is forecast to generate -$6,062,424 in earnings, with the lowest earnings forecast at -$43,504,172 and the highest earnings forecast at $30,132,760.